MedPath

A phase II study of Bevacizumab and Docetaxel for elderly patients advanced Non-Small Cell Lung Cancer

Phase 2
Recruiting
Conditions
on-squamous non-small cell lung cancer
Registration Number
JPRN-UMIN000006322
Lead Sponsor
niversity hospital, Hirosaki University School of Medicine Cardiology,respiratory medicine and nephrology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1)Subjects with interstitial pneumonia or pulmonary fibrosis. 2)Uncontrolled systematic disease 3)Uncontrolled active infection 4)No other active malignancies 5)Concurrent use of steroid therapy 6)Subjects with brain metastases 7)Uncontrolled pleural effusion and ascites 8)have had or require continuous oral administration of hemostat/have had or require injectable administration of hemostat 9)Pregnant patients 10)Have a bleeding diathesis 11)Tumor invasion to major vessels 12)Cavity in tumor 13)History of uncontrolled gastroduodenal ulcer 14)Uncontrolled hypertension 15)Symptomatic heart failure,unstable angina, uncontrolled arrhythmia, myocardial infarction within 1 year 16)Symptomatic cerebrovasucular disease 17)Any other reason that,in the opinion of the investugator precludes the subject from participating in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
RR: response rate
Secondary Outcome Measures
NameTimeMethod
PFS: progression free survival OS: overall survival safety
© Copyright 2025. All Rights Reserved by MedPath